📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-08-10 19:36
712 analysed today
712
Today
133,601
All-time analysed
40,124
Positive
6,284
Negative
79,373
Neutral
7,752
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
24 announcements match the current filters (relevance ≥ 5).
₹3,000 Cr fundraise approved at Wockhardt AGM; Institutional dissent on executive pay
Wockhardt shareholders have approved a massive capital raise of up to ₹3,000 Cr via QIP or other offerings, representing approximately 14.7% of its current market capitalization. While the fundraise passed with 98.95% support, a notable 44.58% of institutional investors voted against the appointment and remuneration of Ms. Zahabiya Khorakiwala as Executive Co-chairperson of a subsidiary. The meeting also ratified material related-party transactions totaling over ₹2,100 Cr and a revision in the Executive Chairman's remuneration ceiling to ₹15 Cr per annum by 2028.
Confidence: HIGH
What changedShareholders have formally authorized a large-scale capital raise and approved a new remuneration structure for top management, alongside high-value inter-subsidiary transactions.
Why it mattersThe ₹3,000 Cr fundraise is pivotal for Wockhardt to deleverage or fund its R&D-heavy strategy (targeting a $9bn global market for ZAYNICH), though the institutional pushback on pay indicates tightening governance expectations.
Fundraise Limit: ₹3,000 CrFundraise vs Market Cap: ~14.7%Institutional Dissent (Res 9): 44.58%RPT Limit (Wockhardt Bio AG): ₹1,000 CrChairman Remuneration Ceiling (FY28): ₹15 Cr
📅 Short termThe approval of the ₹3,000 Cr fundraise provides a clear path for capital infusion, which is likely to be viewed positively by the market despite potential dilution concerns.
📈 Long termThe successful deployment of the approved capital into the novel antibiotic portfolio and doubling of diabetes product capacity could structurally re-rate the company's margins and growth profile.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Significant equity dilution from the ₹3,000 Cr QIP
- High institutional dissent on management remuneration
- Large volume of related-party transactions
Key Highlights
Approved raising additional capital up to ₹3,000 Cr through QIP or private offerings
Material Related Party Transactions with Wockhardt Bio AG approved for up to ₹1,000 Cr
Institutional investors recorded a high dissent of 44.58% against Resolution 9 regarding executive remuneration
Chairman Dr. Habil Khorakiwala's remuneration ceiling revised to ₹15 Cr per annum effective March 2028
Approved two separate RPTs between subsidiaries Wockhardt Bio AG, CP Pharma, and Wockhardt UK for ₹550 Cr each
👀 What to Watch
Investors should monitor the timeline and pricing of the ₹3,000 Cr QIP, as the resulting equity dilution will be significant but necessary to fund the company's shift toward high-margin patented antibiotics and diabetes capacity expansion.
Rs 107 Cr PAT in Q1 FY27: Wockhardt swings to profit; ZAYNICH receives US FDA approval
Wockhardt reported a significant turnaround in Q1 FY27, posting a PAT of Rs 107 Cr compared to a loss of Rs 108 Cr in the same quarter last year. Revenue grew 26% YoY to Rs 929 Cr, driven by a 112% surge in Biotech operations which reached Rs 236 Cr. A major milestone was achieved with the US FDA approval of the novel antibiotic ZAYNICH on May 30, 2026. EBITDA margins expanded to 20.2% from 13.7% YoY, reflecting improved operational efficiency and a shift toward high-margin NCEs.
Confidence: HIGH
What changedWockhardt has transitioned from a loss-making entity to profitability, supported by the first-ever US FDA approval for an India-discovered and developed drug (ZAYNICH).
Why it mattersThe shift toward high-margin novel antibiotics (NCEs) and biosimilars is beginning to impact the bottom line, potentially reducing the company's historical reliance on generic pricing.
Q1 FY27 PAT: Rs 107 CrRevenue Growth (YoY): 26%Biotech Revenue: Rs 236 CrEBITDA Margin: 20.2%ZAYNICH US FDA Approval Date: May 30, 2026
📅 Short termThe stock is likely to see positive momentum following the earnings turnaround and the confirmation of a major US FDA approval for its lead NCE.
📈 Long termStructural shift toward a research-led NCE player targeting a $9 billion global market could lead to sustained margin expansion and business re-rating.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- High debt of Rs 1964 Cr
- Execution risk in global commercialization of NCEs
- Regulatory risks for pending pipeline approvals
Key Highlights
Turnaround to PAT of Rs 107 Cr in Q1 FY27 from a loss of Rs 108 Cr in Q1 FY26.
Biotech segment revenue surged 112% YoY to Rs 236 Cr, now contributing ~25% of total revenue.
EBITDA grew 86% YoY to Rs 188 Cr, with margins expanding by 650 bps to 20.2%.
ZAYNICH (WCK 5222) received US FDA approval on May 30, 2026, for treating cUTI.
India Branded Business grew 21% YoY to Rs 156 Cr, supported by Diabetic and NCE therapies.
👀 What to Watch
Monitor the commercial launch timeline and market uptake of ZAYNICH in the US and India, and track the NDA filing for FOVISCU expected in Q3 FY27.
Rs 107 Cr PAT in Q1 FY27: Wockhardt Turns Profitable with 26% Revenue Growth
Wockhardt reported a significant financial turnaround in Q1 FY27, posting a Profit After Tax (PAT) of Rs 107 Cr compared to a loss of Rs 108 Cr in Q1 FY26. Revenue grew 26% YoY to Rs 929 Cr, while EBITDA surged 86% to Rs 188 Cr, reflecting improved operational efficiency with margins expanding to 20.2%. The growth was primarily driven by the Biotech segment, which grew 112% YoY to Rs 236 Cr, and the India Branded business, which grew 21%. Crucially, the company secured US FDA approval for its novel antibiotic ZAYNICH on May 30, 2026, marking a major milestone for its R&D pipeline.
Confidence: HIGH
What changedWockhardt has transitioned from a loss-making entity to profitability, supported by the first-ever US FDA approval for an Indian-discovered novel antibiotic (ZAYNICH).
Why it mattersThe turnaround validates Wockhardt's long-term R&D strategy and shift toward high-margin patented NCEs, potentially reducing reliance on generic pricing and improving ROCE.
Q1 FY27 Revenue: Rs 929 CrRevenue vs TTM Revenue: 31.5%Q1 FY27 EBITDA Margin: 20.2%Biotech Revenue Growth: 112%ZAYNICH US FDA Approval Date: May 30, 2026
📅 Short termThe stock is likely to react positively to the return to profitability and the milestone US FDA approval for ZAYNICH, which opens a significant global market.
📈 Long termStructural growth depends on the successful global launch of its 6 QIDP-status antibiotics and the planned doubling of diabetes product capacity over the next 24-36 months.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- High debt levels (Rs 1964 Cr)
- Regulatory risks associated with EMA review
- Execution risks in scaling novel drug sales globally
Key Highlights
Reported PAT of Rs 107 Cr in Q1 FY27, a sharp recovery from a loss of Rs 108 Cr in the previous year.
Biotech segment revenue grew 112% YoY to Rs 236 Cr, led by a 146% surge in Emerging Markets.
EBITDA margins expanded to 20.2% in Q1 FY27 from 13.7% in Q1 FY26.
ZAYNICH received US FDA approval on May 30, 2026, for the treatment of cUTI including Pyelonephritis.
India Branded Business grew 21% YoY to Rs 156 Cr, aided by Diabetic and NCE (EMROK) therapies.
👀 What to Watch
Monitor the commercialization timeline and revenue contribution from ZAYNICH in the US and India markets. Watch for the EMA review outcome and the planned NDA filing for FOVISCU in Q3 FY27 to gauge the progress of the NCE pipeline.
Wockhardt Q1 FY27: Turnaround to Rs 107 Cr Net Profit; Revenue Grows 26.6% YoY
Wockhardt Limited reported a significant turnaround in Q1 FY27, posting a consolidated net profit of Rs 107 Cr compared to a net loss of Rs 108 Cr in the same quarter last year. Consolidated revenue from operations grew 26.6% YoY to Rs 960 Cr, although it saw a sequential decline from Rs 1,010 Cr in Q4 FY26. The company demonstrated improved operational efficiency, with total expenses as a percentage of revenue dropping to 87.9% from 101.5% YoY. Finance costs remained stable at Rs 52 Cr, reflecting better capital management post-QIP.
Confidence: HIGH
What changedWockhardt has transitioned from a loss-making entity to a profitable one on a YoY basis, driven by a 26.6% increase in top-line and improved expense control.
Why it mattersThe turnaround is critical for a company with a high debt-to-equity ratio (0.64) and high P/E (155), as it validates the management's strategy to focus on high-margin patented antibiotics and biosimilars.
Consolidated Revenue (Q1 FY27): Rs 960 CrYoY Revenue Growth: 26.6%Consolidated Net Profit: Rs 107 CrQ1 Profit vs TTM PAT: 77.5%Finance Costs: Rs 52 Cr
📅 Short termThe stock is likely to react positively to the sharp YoY turnaround and the return to profitability, confirming the recovery trend seen in late FY26.
📈 Long termLong-term value depends on the successful commercialization of ZAYNICH and other NCEs in global markets, which could structurally re-rate the OPM from the current 17.1%.
⚠ Risk flags
- Sequential revenue decline of 5% compared to Q4 FY26
- High valuation multiples (P/E 155)
- Regulatory risks associated with 12 global manufacturing facilities
Key Highlights
Consolidated Revenue from operations increased to Rs 960 Cr, a 26.6% growth over Rs 758 Cr in Q1 FY26.
Net Profit turned positive at Rs 107 Cr, reversing a loss of Rs 108 Cr in the year-ago period.
Basic Earnings Per Share (EPS) improved to Rs 6.55 from a negative Rs 5.53 in June 2025.
Total expenses were contained at Rs 844 Cr, nearly flat compared to the previous quarter's Rs 843 Cr despite higher YoY volumes.
Standalone revenue contributed Rs 561 Cr to the consolidated total, showing strong domestic/direct performance.
👀 What to Watch
Investors should monitor the sustainability of these margins in upcoming quarters and track the regulatory progress of the novel antibiotic WCK 5222 in the US market. The shift from generic pricing to innovation-led products is the key driver to watch.
Wockhardt Reports 51% EBITDA Growth and US FDA Approval for Novel Antibiotic Zaynich
Wockhardt Limited has transitioned from a liquidity management phase to a growth phase, reporting a top line of INR 3,373 crores and an EBITDA of INR 630 crores (18.6% margin). The company has significantly deleveraged, achieving a net debt-to-equity ratio of 0.1 with cash equivalents of INR 662 crores. A major milestone is the US FDA approval of Zaynich, the first Indian research product to receive such approval, with launches planned for the US and India in the current year. The company is also scaling its diabetes biosimilar platform, targeting a $7-8 billion market in India and emerging markets.
Key Highlights
EBITDA increased by 51% to INR 630 crores, with margins expanding from 5.4% to 18.6% over three years.
Zaynich approved by US FDA, marking the first Indian research product to achieve this milestone.
Net debt-to-equity ratio reduced to 0.1 with a cash balance of INR 662 crores.
Emerging market business grew by 35%, while the biosimilar/biotech segment saw 27% growth.
Pipeline includes 5 new diabetes biosimilar products including Semaglutide and Degludec.
👀 What to Watch
Investors should focus on the commercial rollout of Zaynich in the US and India as a primary value driver. The company's successful debt reduction and improved EBITDA margins suggest a stabilized platform for scaling its high-margin innovation and biosimilar portfolios.
Wockhardt Reports 51% EBITDA Growth in FY26 and US FDA Approval for Novel Antibiotic Zaynich
Wockhardt Limited reported a strong financial performance for FY26 with total income reaching INR 3,373 Cr and EBITDA growing 51% YoY to INR 630 Cr. The company has successfully transitioned its focus from US generics to high-margin specialty products and novel antibiotics, resulting in a healthy Net Debt to Equity ratio of 0.10. A major growth catalyst is the US FDA and CDSCO approval of Zaynich, a novel antibiotic targeting a market of 1.2 million hospital infections in the USA. Additionally, the company is scaling its biotech franchise with a 2x increase in Human Insulin production capacity.
Key Highlights
FY26 EBITDA increased by 51% YoY to INR 630 Cr with margins improving to 18.6%.
Zaynich received US FDA and CDSCO approval, targeting a significant market of ~1.2 million Gram-negative infections in the US.
Net Debt to Equity ratio stands at a low 0.10 with cash and cash equivalents of INR 662 Cr as of March 2026.
Biotech production capacity scaled up 2x for Human Insulin and 1.5x for Glargine to meet rising global demand.
Strategic exit from the underperforming US generics business has sharpened the portfolio focus on high-margin core products.
👀 What to Watch
Investors should closely track the commercial launch and market penetration of Zaynich in the US and India as it is a high-margin, first-in-class asset. The company's improved balance sheet and pivot toward novel antibiotics suggest a positive long-term growth trajectory.
Wockhardt to Hold Strategic Investor Meet on June 4, 2026, to Discuss Zaynich and Global Business
Wockhardt Limited has scheduled an in-person Investor Meet on June 4, 2026, at the NSE Exchange Plaza in Mumbai starting at 4:00 PM IST. The meeting will feature a strategic overview from Managing Director Dr. Murtaza Khorakiwala and specific presentations on the US and India business segments. A significant portion of the agenda is dedicated to 'Zaynich,' a key product in their pipeline, suggesting upcoming milestones or commercialization updates. The entire top management, including Founder Chairman Dr. Habil Khorakiwala, will be present for a Q&A session.
Key Highlights
Investor Meet scheduled for June 4, 2026, at 4:00 PM IST at Atrium, NSE Exchange Plaza, BKC.
Agenda includes a strategic overview and detailed presentations on US and India business operations.
Specific focus on 'Zaynich' with dedicated presentations and films, indicating its critical role in the company's future growth.
Full leadership team present for Q&A, including Founder Chairman Dr. Habil Khorakiwala and MD Dr. Murtaza Khorakiwala.
👀 What to Watch
Investors should closely monitor the commentary regarding the 'Zaynich' drug pipeline and the US business turnaround strategy following the meet. This event could provide significant clarity on the company's medium-term growth catalysts and debt management.
Wockhardt Receives US FDA Approval for ZAYNICH (NCE) for cUTI Treatment
Wockhardt has achieved a historic milestone by receiving US FDA approval for ZAYNICH (cefepime and zidebactam), a novel intravenous antibiotic for complicated urinary tract infections (cUTI). In Phase 3 trials, ZAYNICH demonstrated a superior composite cure rate of 89.0% compared to 68.4% for meropenem, a treatment difference of 20.6%. This is the first New Chemical Entity (NCE) fully developed and commercialized by an Indian pharmaceutical company to receive FDA approval. The drug targets a significant market, as cUTI accounts for over 600,000 hospitalizations annually in the U.S.
Key Highlights
US FDA approved ZAYNICH for treating adult patients with cUTI including pyelonephritis.
Phase 3 ENHANCE-1 trial showed 89.0% clinical cure rate vs 68.4% for the comparator meropenem.
First New Chemical Entity (NCE) fully developed by an Indian company to receive US FDA approval.
ZAYNICH received DCGI approval in India on May 27, 2026, and has a pending MAA with the EMA.
The drug addresses a critical need in the U.S. where 2.8 million antimicrobial-resistant infections occur annually.
👀 What to Watch
This is a major value-unlocking event for Wockhardt; investors should monitor the commercial launch strategy and market penetration in the U.S. The superior efficacy data and NCE status provide a significant competitive advantage in the global anti-infective market.
Wockhardt Receives CDSCO Approval for Breakthrough Antibiotic Zaynich® in India
Wockhardt has received marketing authorization from the Indian drug regulator (CDSCO) for its indigenously developed antibiotic, Zaynich® (Zidebactam/Cefepime). In Phase 3 clinical trials, Zaynich® demonstrated a superior 89% efficacy rate compared to 68.4% for the standard treatment, meropenem. This approval targets complicated urinary tract infections and addresses high-resistance pathogens where current options are limited. The company has also submitted for US and EU approvals, signaling significant global market potential.
Key Highlights
CDSCO grants marketing authorization for Zaynich® to treat cUTI and Gram-negative bacteremia.
Phase 3 study showed 89% clinical cure rate, outperforming meropenem by a 20.6% margin.
Zaynich® is uniquely designed to combat metallo-β-lactamase (MBL) mediated resistance prevalent in India.
NDA and MAA submissions for the drug are currently under regulatory review in the US and EU.
Wockhardt has a pipeline of six antibiotics with US FDA QIDP designation at various stages.
👀 What to Watch
This is a significant positive development that validates Wockhardt's R&D pipeline and provides a high-value entry into the critical care segment. Investors should monitor the commercial launch in India and upcoming regulatory decisions from the US FDA and EU.
ICRA Upgrades Wockhardt's Long-Term Credit Rating to 'A-' from 'BBB'
ICRA Limited has upgraded Wockhardt Limited's long-term credit rating from BBB (Positive) to A- (Stable), signaling a significant improvement in the company's creditworthiness. The short-term rating has also been upgraded from A3+ to A2+, reflecting a stronger liquidity profile and better access to short-term capital. This upgrade is supported by improved financial performance, a healthy market position in India and Europe, and a comfortable capital structure. The rating agency specifically noted the potential of the company's New Chemical Entities (NCEs) and value-accretive products to drive future scale.
Key Highlights
Long-term fund-based term loan rating upgraded to A- (Stable) from BBB (Positive)
Short-term ratings for fund and non-fund based limits upgraded to A2+ from A3+
Upgrade driven by improved financial metrics and scale expansion of New Chemical Entities (NCEs)
ICRA highlighted a comfortable capital structure and adequate liquidity position
Healthy market position maintained in formulation segments across India, Europe, and emerging markets
👀 What to Watch
The credit upgrade is a positive indicator of Wockhardt's operational turnaround and financial discipline. Investors should monitor the commercialization of their NCE pipeline, which remains a key driver for further valuation re-rating.
Wockhardt Designates Three Seasoned Leaders as Senior Management Personnel
Wockhardt Limited has designated three high-caliber professionals as Senior Management Personnel (SMP) effective May 4, 2026, to lead its India Business, NCE, and Biotechnology divisions. Ms. Annapurna Das, with over 26 years of experience at Takeda and Sanofi, will head the India Business and Emerging Markets. Additionally, Mr. Om Narayan and Mr. Sunil Soni, both bringing nearly 30 years of expertise in biotech R&D and manufacturing from firms like Serum Institute and Mylan, have been designated as Senior VPs. This strategic leadership reinforcement highlights Wockhardt's focus on scaling its super-specialty portfolio and biosimilar capabilities.
Key Highlights
Ms. Annapurna Das appointed as President (India Business & Emerging Markets) with 26+ years of pharma leadership experience.
Mr. Om Narayan designated as Senior VP (Biotech Research Centre) with nearly 30 years in R&D and vaccine approvals.
Mr. Sunil Soni designated as Senior VP (Biotechnology) with 30 years of experience in manufacturing and process development.
The new leadership team brings combined experience from global giants like Takeda, Sanofi, GSK, and Serum Institute.
Strategic focus placed on New Chemical Entities (NCE), Biologics, and high-growth emerging markets.
👀 What to Watch
Investors should view these high-profile appointments as a positive signal of Wockhardt's commitment to its NCE and Biotech growth pillars. Monitor the execution of the India business strategy and progress in the biotech pipeline under this new leadership.
Wockhardt Reports Turnaround with FY26 PBT of Rs 238 Cr and 30% Q4 Revenue Growth
Wockhardt Limited reported a significant financial turnaround for FY26, posting a Profit Before Tax (PBT) of Rs 238 crore compared to a loss of Rs 16 crore in the previous year. Revenue for Q4FY26 grew by 30% to Rs 965 crore, driven by robust performance in the Biotech segment which surged 126% YoY. The company's EBITDA margins improved substantially to 18.7% for the full year from 13.8% in FY25. Key growth drivers included the India branded business and emerging markets, alongside progress in its novel antibiotics pipeline like Zaynich and Emrok.
Key Highlights
Reported a consolidated PAT of Rs 199 crore for FY26 against a loss of Rs 57 crore in FY25
Q4FY26 EBITDA grew by 147% YoY to Rs 196 crore with margins expanding to 20.3%
Biotech operations recorded a massive 126% growth in Q4FY26, reaching Rs 252 crore
Emerging Markets revenue jumped 124% in Q4FY26 to Rs 320 crore, fueled by insulin analogs
Five novel antibiotics completed Phase 3 trials, with Zaynich receiving EMA accelerated assessment
👀 What to Watch
Investors should view this turnaround and the progress of the NCE (Novel Chemical Entity) pipeline as a strong positive signal. Monitor the regulatory approvals for Zaynich in the US and EU, as these could be significant long-term value drivers.
Wockhardt Reports FY26 Turnaround with ₹317 Cr Net Profit; Board Approves New Fundraise
Wockhardt Limited has reported a significant financial turnaround for the fiscal year ended March 31, 2026, posting a standalone net profit of ₹317 crore compared to a loss of ₹12 crore in the previous year. Annual revenue from operations grew by 24% to ₹1,739 crore, driven by strong quarterly performance where Q4 revenue hit ₹516 crore. The company also resolved a legal dispute with Dr. Reddy's Laboratories, resulting in a ₹35 crore exceptional gain. Furthermore, the board has approved an enabling resolution to raise fresh capital through equity or convertible securities to support future growth.
Key Highlights
Standalone Net Profit for FY26 reached ₹317 crore, a sharp recovery from a ₹12 crore loss in FY25.
Annual Revenue from Operations increased to ₹1,739 crore in FY26 from ₹1,402 crore in the previous fiscal.
Q4 FY26 Net Profit stood at ₹167 crore, up significantly from ₹40 crore in the same quarter last year.
Recognized a net gain of ₹35 crore as an exceptional item following a final settlement with Dr. Reddy's Laboratories.
Board approved a proposal for raising funds via QIP, preferential allotment, or other equity-linked securities.
👀 What to Watch
The shift from loss to significant profitability and the resolution of legal overhangs are strong positive indicators; investors should monitor the terms of the upcoming fundraise for potential equity dilution.
Wockhardt Reports FY26 Turnaround with ₹317 Cr Net Profit; Board Approves Fundraising
Wockhardt Limited reported a significant financial turnaround for the fiscal year ended March 31, 2026, posting a standalone net profit of ₹317 crore compared to a loss of ₹12 crore in the previous year. Revenue from operations for Q4 FY26 grew by 45% year-on-year to ₹516 crore, supported by a ₹35 crore exceptional gain from a legal settlement with Dr. Reddy's Laboratories. The Board also approved an enabling proposal to raise fresh capital through equity or convertible securities to support future growth and balance sheet strength.
Key Highlights
Standalone Revenue for Q4 FY26 increased 45% YoY to ₹516 crore from ₹355 crore.
Full-year FY26 Standalone Net Profit reached ₹317 crore, reversing a ₹12 crore loss in FY25.
Recognized an exceptional gain of ₹35 crore in Q4 FY26 following a final settlement with Dr. Reddy's Laboratories.
Board approved an enabling resolution for raising funds via QIP, preferential allotment, or other equity-linked instruments.
Annual Basic EPS improved to ₹19.54 in FY26 from a negative ₹0.76 in FY25.
👀 What to Watch
Investors should take note of the strong operational turnaround and the resolution of long-standing legal disputes. Monitor the details of the proposed fundraise for potential equity dilution and the company's plan for capital deployment.
Wockhardt's Zaynich® Receives Favorable SEC Recommendation for Gram-Negative Infections
Wockhardt has received a positive recommendation from the CDSCO's Subject Expert Committee for its novel antibiotic, Zaynich® (Zidebactam/Cefepime), moving it closer to final DCGI approval in India. The drug, developed over 15 years by 150+ scientists, demonstrated superiority over meropenem in a global Phase 3 study involving 530 patients across 64 sites. Additionally, real-world studies in India showed a clinical efficacy rate of over 97% against meropenem-resistant infections. With US and EU regulatory reviews also in advanced stages, this marks a significant milestone for the company's R&D-led growth strategy.
Key Highlights
SEC recommendation paves the way for final DCGI marketing approval in India for Gram-negative infections
Global Phase 3 study of 530 patients showed superiority over meropenem in combined clinical and microbiological cure
Real-world study across 15 Indian hospitals demonstrated over 97% clinical efficacy in meropenem-resistant cases
NDA in the United States and MAA in the European Union are currently in advanced stages of review
The drug is part of a 6-product portfolio with US FDA Qualified Infectious Disease Product (QIDP) status
👀 What to Watch
This is a major positive milestone that de-risks Wockhardt's flagship R&D asset; investors should monitor the final DCGI approval and commercial launch timelines. Success in the Indian market could serve as a precursor to potential high-value approvals in the US and EU markets.
Wockhardt Q3 FY26: Revenue up 22% to ₹888 Cr, EBITDA Surges 72% to ₹173 Cr
Wockhardt reported a strong financial performance for Q3 FY26, with revenue growing 22% YoY to ₹888 crore. EBITDA saw a significant jump of 72% to ₹173 crore, with margins expanding to 19.5% from 13.8% in the previous year. Profit After Tax (PAT) improved to ₹61 crore compared to ₹20 crore in Q3 FY25. The growth was primarily driven by a 96% surge in Biotech operations and robust performance in Emerging Markets and the India Branded Business.
Key Highlights
Revenue increased 22% YoY to ₹888 crore; EBITDA grew 72% to ₹173 crore.
Biotech segment revenue reached ₹213 crore, with Emerging Market biotech growing over 50%.
India Branded Business grew 28% to ₹146 crore, aided by Diabetic therapy and NCE (EMROK).
Novel antibiotic Zaynich received EMA Accelerated Assessment; Foviscu successfully met Phase 3 endpoints.
Exceptional items of ₹107 crore for 9M FY26 include impacts from US entity liquidation and the New Labour code.
👀 What to Watch
Investors should focus on the company's transition toward high-margin biotech and novel antibiotics, particularly the upcoming global launches of Zaynich and Insulin analogs. The significant margin expansion and R&D breakthroughs suggest a positive turnaround trajectory.
Wockhardt Q3 Standalone Revenue Up 32% YoY to ₹430 Cr; Reports Profit of ₹28 Cr
Wockhardt Limited reported a strong year-on-year performance for the quarter ended December 31, 2025, with standalone revenue growing 32% to ₹430 crore. The company achieved a standalone net profit of ₹28 crore, marking a significant turnaround from a loss of ₹22 crore in the same quarter last year. For the nine-month period ending December 2025, the company has turned profitable with a net profit of ₹150 crore compared to a loss of ₹52 crore in the previous year. Profitability for the quarter was slightly impacted by a ₹10 crore exceptional charge related to the new Indian Labour Code compliance.
Key Highlights
Standalone revenue from operations increased 32.3% YoY to ₹430 crore from ₹325 crore.
Reported a standalone net profit of ₹28 crore vs a loss of ₹22 crore in the year-ago period.
Nine-month standalone net profit reached ₹150 crore, a sharp recovery from a ₹52 crore loss in the prior year.
Recognized an exceptional charge of ₹10 crore due to the impact of consolidated Labour Codes.
Basic EPS for the nine-month period improved to ₹9.24 compared to a negative ₹3.36 in the previous year.
👀 What to Watch
The standalone turnaround and consistent revenue growth are positive signals for the company's core Indian operations. Investors should now focus on the consolidated results to assess the performance of international subsidiaries and the overall debt reduction progress.
Wockhardt President of Manufacturing, Quality & R&D Dr. Sanjeev Kumar Sharma Resigns
Dr. Sanjeev Kumar Sharma, the President of Manufacturing, Quality & R&D at Wockhardt Limited, has resigned from his position effective February 2, 2026. As a designated Senior Management Personnel (SMP), his departure impacts three critical pillars of the company's operations. The resignation is attributed to personal reasons, and he will cease to be an SMP of the company. Investors should note that this role is vital for maintaining regulatory standards and product development pipelines.
Key Highlights
Dr. Sanjeev Kumar Sharma resigned as President - Manufacturing, Quality & R&D effective February 2, 2026.
The official reason provided for the resignation is personal reasons.
The role is classified as Senior Management Personnel (SMP) under SEBI Listing Regulations.
The departure covers oversight of three major departments: Manufacturing, Quality, and R&D.
👀 What to Watch
Investors should monitor the company's announcement regarding a successor to ensure operational continuity in R&D and quality compliance. No immediate portfolio changes are suggested, but management stability is a key factor for the stock.
Wockhardt's Foviscu Antibiotic Meets Phase 3 Primary Endpoint with 93.23% Clinical Cure Rate
Wockhardt has announced that its fifth novel antibiotic, Foviscu (WCK 4282), successfully met its primary endpoint in a pivotal Phase 3 trial for treating complicated urinary tract infections. The drug demonstrated a clinical cure rate of 93.23%, matching the 92.31% achieved by the gold-standard meropenem, while showing a well-tolerated safety profile. This milestone is significant as it addresses high-resistance ESBL pathogens in a market where approximately 65 lakh treatment courses of similar antibiotics are used annually in India. The drug has already received QIDP designation from the US FDA, enhancing its global commercial potential.
Key Highlights
Foviscu achieved a 93.23% clinical cure rate versus 92.31% for the gold-standard meropenem in Phase 3 trials.
This is Wockhardt's 5th proprietary antibiotic to successfully complete a registration-enabling Phase 3 study.
The trial targeted ESBL-producing pathogens, which accounted for 51.4% of the Enterobacterales isolates in the study.
Foviscu addresses a large domestic market where 65 lakh treatment courses of similar antibiotics are used annually.
The product holds US FDA Qualified Infectious Disease Product (QIDP) status, providing regulatory advantages.
👀 What to Watch
Investors should monitor the upcoming regulatory filing and approval timelines for Foviscu, as it represents a significant addition to Wockhardt's commercial antibiotic portfolio. The successful Phase 3 result de-risks a key part of the company's R&D pipeline.
Wockhardt Files MAA with EMA for Novel Antibiotic WCK 5222; Eligible for Accelerated Assessment
Wockhardt has filed a Marketing Authorisation Application (MAA) with the European Medicines Agency (EMA) for its novel antibiotic WCK 5222 (Zaynich®) on January 5, 2026. The EMA has granted the drug 'Accelerated Assessment' status, which will shorten the review timeline across 30 European countries including the EU and EEA. This follows a successful global Phase III trial and a previous NDA filing with the US FDA under fast-track review. As the first Indian-developed New Chemical Entity (NCE) to seek pan-European approval, this marks a major commercial milestone for the company's R&D pipeline.
Key Highlights
WCK 5222 filed with EMA for marketing authorization across 30 European countries on January 5, 2026.
Granted 'Accelerated Assessment' by EMA, allowing for an abridged review period due to high unmet medical needs.
The drug is a fixed-dose combination of Zidebactam (1 g) and Cefepime (2 g) targeting multi-drug resistant infections.
WCK 5222 is already under fast-track review by the US FDA and has been filed with Indian regulatory authorities.
Wockhardt's portfolio includes 6 antibiotics with US FDA QIDP designation, supporting its 77% international revenue base.
👀 What to Watch
Investors should monitor the EMA's review progress as the accelerated status could lead to a faster commercial launch in Europe. This development significantly strengthens Wockhardt's position in the global high-end antibiotic market.
